Table 4.

CDR and psychological test scores for APOE4 (−) subjects ^a.

	Startup		Follow-Up		Treatment × Time Interaction b
	Active	Placebo	Active	Placebo	Active	Placebo	p Value
MMSE	27.6 ± 2.1	27.3 ± 2.0	27.2 ± 2.6	26.8 ± 3.1	−0.41 ± 1.7	−0.46 ± 1.9	0.840
gloCDR	0.5	0.5	0.44 ± 0.17	0.46 ± 0.14	−0.059 ± 0.17	−0.038 ± 0.14	0.477
CDRsob	0.88 ± 0.49	0.85 ± 0.47	0.82 ± 0.43	0.92 ± 0.64	−0.059 ± 0.43	0.077 ± 0.76	0.602
WMS-1	7.2 ± 4.8	7.5 ± 4.2	9.4 ± 4.9	9.5 ± 6.1	2.2 ± 2.3	2.0 ± 3.5	0.993
WMS-2	5.1 ± 4.8	6.3 ± 4.6	6.8 ± 5.6	8.0 ± 6.5	1.7 ± 2.9	1.7 ± 3.3	0.997
ADAS	12.9 ± 8.2	13.6 ± 5.9	13.5 ± 8.2	13.4 ± 7.1	0.54 ± 3.3	−0.20 ± 4.3	0.697
GDS	2.9 ± 2.0	2.8 ± 3.1	3.2 ± 3.1	2.5 ± 2.1	0.29 ± 2.8	−0.30 ± 2.0	0.676

^a We performed the same statistical analysis, described in Table 2. ^b The change between start-up and follow-up.